430 related articles for article (PubMed ID: 17137007)
1. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
2. Mutations of BRCA genes in hereditary breast and ovarian cancer.
Radice P
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):9-12. PubMed ID: 12585647
[TBL] [Abstract][Full Text] [Related]
3. Optimal selection of individuals for BRCA mutation testing.
Evans DG; Lalloo F; Eccles D
J Clin Oncol; 2006 Jul; 24(20):3311; author reply 3311-2. PubMed ID: 16829657
[No Abstract] [Full Text] [Related]
4. [In familial breast or ovarian carcinoma: normal cancer prevention is not enough].
Riem L
MMW Fortschr Med; 2004 Apr; 146(15):12. PubMed ID: 15373015
[No Abstract] [Full Text] [Related]
5. DNA testing. Genetic screen misses mutations in women at high risk of breast cancer.
Stokstad E
Science; 2006 Mar; 311(5769):1847. PubMed ID: 16574828
[No Abstract] [Full Text] [Related]
6. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
7. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.
Quinn GP; Vadaparampil ST; Bower B; Friedman S; Keefe DL
Minerva Med; 2009 Oct; 100(5):371-83. PubMed ID: 19910890
[TBL] [Abstract][Full Text] [Related]
8. Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
Capalbo C; Buffone A; Vestri A; Ricevuto E; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
J Clin Oncol; 2007 Jun; 25(18):2632-4; author reply 2634-5. PubMed ID: 17577048
[No Abstract] [Full Text] [Related]
9. BRCA1 and BRCA2 cancer risks.
Antoniou AC; Pharoah PD; Easton DF; Evans DG
J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
[No Abstract] [Full Text] [Related]
10. [Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy].
Levanat S; Cvok ML
Lijec Vjesn; 2010; 132(1-2):34-7. PubMed ID: 20359158
[TBL] [Abstract][Full Text] [Related]
11. Cancer. A risky business--assessing breast cancer risk.
Levy-Lahad E; Plon SE
Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
[No Abstract] [Full Text] [Related]
12. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J
Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605
[TBL] [Abstract][Full Text] [Related]
14. Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.
James PA; Harris M; Lindeman GJ; Mitchell G
J Med Genet; 2008 Nov; 45(11):765-6. PubMed ID: 18978334
[No Abstract] [Full Text] [Related]
15. 'Indirect' BRCA1/2 testing: a useful approach in hereditary breast and ovarian cancer families without a living affected relative.
Cruger DG; Kruse TA; Gerdes AM
Clin Genet; 2005 Sep; 68(3):228-33. PubMed ID: 16098011
[TBL] [Abstract][Full Text] [Related]
16. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
17. One risk fits all?
De Bock GH; Mourits MJ; Oosterwijk JC
J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
[No Abstract] [Full Text] [Related]
18. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
19. Improving surveillance and quality of life of BRCA mutation carriers.
Loman N; Borg A
J Clin Oncol; 2010 Aug; 28(22):e376-7. PubMed ID: 20458044
[No Abstract] [Full Text] [Related]
20. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
